Drug profile · INN
tarlatamab-dlle
IMDELLTRA
tarlatamab-dlle (IMDELLTRA) is a delta-like protein 3 binding agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — tarlatamab-dlle
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
tarlatamab-dlle (IMDELLTRA) is a delta-like protein 3 binding agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Delta-like protein 3 binding agent
Primary target: Delta-like protein 3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tarlatamab-dlle?
tarlatamab-dlle (IMDELLTRA) is a delta-like protein 3 binding agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for tarlatamab-dlle?
IMDELLTRA is a marketed brand name for tarlatamab-dlle. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tarlatamab-dlle?
tarlatamab-dlle has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.